---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174459"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:54:32.223260+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M

## Summary
- Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
- Adjusted EBITDA $1.3M (down from $2.9M); operating loss $10.6M vs $8.5M.
- Installed base grew to 3,295 instruments (146 new units); launched Aurora Evo system.
- Recurring revenue up 16% YoY; repurchased $4.5M in stock during Q2.
- 2025 revenue guidance narrowed to $196-205M (flat to -2% growth over 2024).

## SEC filing metadata
- accession: 0001193125-25-174459
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312525174459/0001193125-25-174459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312525174459/d27070d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174459
- JSON: https://secwatch.observer/filing/0001193125-25-174459.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.